Vutrisiran was tested in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), where function of the heart muscles is restricted due to the accumulation of irregular proteins.
Tag Archive for: transthyretin amyloid cardiomyopathy
Additional analyses from BridgeBio Pharma’s late-stage study show the oral drug candidate’s improved clinical outcomes in transthyretin amyloid cardiomyopathy patients.
The FDA on Monday denied approval of Alnylam Pharmaceuticals’ siRNA therapy Onpattro (patisiran) for the treatment of cardiomyopathy of transthyretin-mediated amyloidosis.
The late-stage results for acoramidis, BridgeBio’s transthyretin amyloid cardiomyopathy candidate, indicate significant survival, functional and biomarker improvements over placebo.
The U.S. Supreme Court on Monday turned away Pfizer Inc.’s bid to revive its plan to cover out-of-pocket expenses of Medicare patients for drugs costing $225,000 a year to treat a rare heart condition after federal officials found that the drugmaker’s arrangement could amount to illegal kickbacks.